SCCM Resource Library-Phase 2 Study Interim Results of RBT-1 Effect on Postoperative Course in Elective CABG/Valve Surgery

Phase 2 Study Interim Results of RBT-1 Effect on Postoperative Course in Elective CABG/Valve Surgery

Video Transcription

Video Summary

In this video transcript, cardiac surgeon Andrei Lamy presents the results of a Phase II study on a drug called RBT1. The drug is a stannous protoporphine with iron sucrose and acts as a pharmacological preconditioning agent. The study aimed to induce a protective response in patients undergoing cardiac surgery and found that RBT1 increased important biomarkers and resulted in a reduction in ICU time and readmissions. Other benefits included shorter ventilator days and length of hospital stay, as well as reduced incidences of atrial fibrillation and troponin levels. The study plans to move on to Phase III trials and invites interested participants to contact the researchers.

Asset Subtitle

Cardiovascular, Profcedures, 2023

Asset Caption

Type: star research | Star Research Presentations: Cardiovascular (SessionID 30001)

Meta Tag

Content Type Presentation

Knowledge Area Cardiovascular

Knowledge Area Profcedures

Membership Level Professional

Membership Level Select

Tag Cardiovascular

Tag Surgery

Year 2023

Keywords

cardiac surgery

RBT1

pharmacological preconditioning agent

biomarkers

Phase III trials

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.